Principles of Pediatric ART

  • Pediatric antiretroviral therapy (ART) aims to achieve sustained viral load suppression ($<50\text{ copies/mL}$), preserve CD4 counts, prevent disease progression, and allow normal growth and development.
  • Current First-Line Standard: Anchored by second-generation Integrase Strand Transfer Inhibitors (INSTIs)—specifically Dolutegravir (DTG)—providing rapid viral suppression, high genetic barrier to resistance, minimal drug interactions, and child-friendly dispersible formulations.
  • WHO & NACO Guidelines: Universal first-line recommendation for DTG-based regimens across all pediatric age and weight tiers down to $3\text{ kg}$ and 4 weeks of age.

Dolutegravir (DTG) In Pediatrics

1. Landmark Evidence: The ODYSSEY Trial (NEJM 2021)

  • Multicenter randomized non-inferiority trial in infants, children, and adolescents weighing $\ge 14\text{ kg}$ (and a subsequent low-weight cohort down to $3\text{ kg}$).
  • Compared DTG-based ART vs standard-of-care (mostly LPV/r or NVP/EFV).
  • Findings:
    • Treatment failure by 96 weeks occurred in $14\%$ of DTG arm vs $22\%$ of standard-of-care ($p=0.004$, superiority).
    • Significantly better lipid profiles (no hypercholesterolemia or hypertriglyceridemia seen with LPV/r).
    • Rapid viral suppression ($<50\text{ copies/mL}$) achieved within 4 to 8 weeks.
    • Zero emergent integrase inhibitor resistance mutations among children who failed DTG.

2. Dispersible Formulation & Dosing

  • DTG 10 mg scored dispersible tablets: Can be dissolved in $5–10\text{ mL}$ of clean drinking water, breast milk, or swallowed whole; sweet strawberry flavor with high acceptability.
  • WHO / NACO Pediatric Weight-Band Dosing (Once Daily):
Weight BandDTG 10 mg Dispersible TabletsTotal Daily Dose
$3\text{ to }5.9\text{ kg}$1 tablet once daily$10\text{ mg}$
$6\text{ to }9.9\text{ kg}$1.5 tablets once daily$15\text{ mg}$
$10\text{ to }13.9\text{ kg}$2 tablets once daily$20\text{ mg}$
$14\text{ to }19.9\text{ kg}$2.5 tablets once daily (or 1 $\times$ 25 mg film-coated)$25\text{ mg}$
$\ge 20\text{ kg}$Adult 50 mg film-coated tablet once daily$50\text{ mg}$

Note on TB Co-infection: If receiving Rifampicin (strong CYP3A4 and UGT1A1 inducer), double the DTG dose (give the weight-band dose twice daily instead of once daily). Continue twice-daily dosing for 2 weeks after stopping Rifampicin.


Preferred Pediatric First-Line ART Regimens (WHO / NACO)

flowchart TD
    A["HIV-Infected Child Confirmed"] --> B{"Weight & Age Tier"}
    
    B -->|"< 30 kg and ≥ 3 kg (≥ 4 weeks)"| C["<b>Preferred First-Line Regimen:</b><br>Abacavir (ABC) + Lamivudine (3TC) + Dolutegravir (DTG 10 mg DT)<br><i>(Dual FDC ABC/3TC 120/60 mg DT + DTG 10 mg DT)</i>"]
    
    B -->|"≥ 30 kg (Adolescent)"| D["<b>Preferred First-Line Regimen (TLD Single-Pill FDC):</b><br>Tenofovir Disoproxil Fumarate (TDF 300 mg) +<br>Lamivudine (3TC 300 mg) +<br>Dolutegravir (DTG 50 mg)"]
    
    B -->|"< 4 weeks or < 3 kg"| E["<b>Neonatal Regimen:</b><br>Zidovudine (AZT) + Lamivudine (3TC) + Nevirapine (NVP)<br><i>Switch to ABC + 3TC + DTG at 4 weeks / 3 kg</i>"]
    
    C --> F{"Rifampicin TB Co-Treatment?"}
    F -->|"Yes"| G["Double DTG frequency to <b>Twice Daily</b> (BID)"]
    F -->|"No"| H["Standard Once Daily DTG"]
  • Dual Fixed-Dose Combination (FDC): ABC/3TC ($120/60\text{ mg}$) dispersible tablet taken once daily alongside DTG 10 mg DT.
  • Older Legacy Regimens Obsolete: Lopinavir/ritonavir syrup (bad taste, 42% alcohol, required refrigeration) and Efavirenz (neuropsychiatric toxicity, high baseline primary resistance) are no longer recommended as first-line options.

Prevention Of Mother-To-Child Transmission (PMTCT) Updates

  • Maternal ART: Lifelong TLD (Tenofovir + Lamivudine + Dolutegravir) initiated immediately at diagnosis during pregnancy or breastfeeding, regardless of CD4 count or gestational age.
  • Risk Stratification of HIV-Exposed Infants (HEI):
Risk StratificationCriteriaInfant Prophylaxis Regimen
Low-Risk InfantMother on ART for $\ge 4\text{ weeks}$ prior to delivery AND viral load suppressed ($<50\text{ copies/mL}$ or $<1,000\text{ copies/mL}$).Daily Nevirapine (NVP) for 6 weeks.
High-Risk InfantMother received $<4\text{ weeks}$ ART; viral load $>1,000\text{ copies/mL}$; newly diagnosed at delivery; or untreated.Dual Prophylaxis: Daily AZT + Daily NVP for 6 weeks, followed by NVP alone for an additional 6 weeks (total 12 weeks), or continuing until 1 week after cessation of all breastfeeding.
  • Infant Feeding: Exclusive breastfeeding (EBF) for the first 6 months with maternal ART adherence, followed by complementary foods with continued breastfeeding up to 24 months or beyond.

Early Infant Diagnosis (EID) Schedule (NACO / WHO)

  1. At Birth ($0–48\text{ hours}$): Performed for high-risk infants using Dried Blood Spot (DBS) Total Nucleic Acid (DNA/RNA) PCR.
  2. At 6 Weeks: Routine DNA PCR at first vaccination visit for all HEI.
  3. At 6 Months: Second DNA PCR testing.
  4. At 18 Months (or 6 weeks after cessation of breastfeeding): Confirmatory HIV antibody test (rapid ELISA).
  5. Confirmation: Any positive virological test (PCR) requires immediate collection of a second specimen for confirmatory PCR; do not delay ART initiation while awaiting the confirmation result.

Pipeline & Long-Acting Therapies

  • Cabotegravir + Rilpivirine (CAB/RPV) Long-Acting Injectable:
    • Approved for adolescents $\ge 12\text{ years}$ and $\ge 35\text{ kg}$ who are virologically suppressed on oral therapy.
    • Administered as intramuscular injections every 2 months, liberating adolescents from the daily pill stigma.
  • Lenacapavir: First-in-class multi-stage HIV capsid inhibitor; administered subcutaneously every 6 months; currently in clinical trials for heavily treatment-experienced youth and as ultra-long-acting PrEP.
  • Pediatric TAF/FTC/DTG: Tenofovir Alafenamide (TAF) combinations being evaluated to eliminate bone and renal toxicity associated with TDF in younger children.